GLP-1 and SGLT2 drugs — could significantly reduce the risk of developing dementia in life, a large new study has found.

The Centers for Medicare and Medicaid Services (CMS) announced Friday it will not be finalizing a rule proposed by the Biden ...

The Centers for Medicare and Medicaid Services said it would not cover the medications under Medicare’s Part D coverage.

Health and Human Services Secretary Robert F. Kennedy Jr. has been critical of the drugs, instead placing a focus on ...

Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Trump officials reject Medicare coverage ...

CMS ends Biden-era proposal to expand Medicare coverage of anti-obesity drugs. Seniors continue paying out of pocket for ...

Dozens of trials testing GLP-1 drugs like semaglutide, the medicine in Ozempic and Wegovy, against a placebo suggest that ...

I’M MINDY BASARA IN TODAY’S MEDICAL ALERT, WEIGHT LOSS AND DIABETES DRUGS LIKE OZEMPIC WEGOVY AND ZYBAN ARE ALL THE RAGE RIGHT NOW. AND TO HELP BETTER UNDERSTAND WHAT’S HAPPENING WITH THESE ...

I’M MINDY BASARA IN TODAY’S MEDICAL ALERT, WEIGHT LOSS AND DIABETES DRUGS LIKE OZEMPIC WEGOVY AND ZYBAN ARE ALL THE RAGE RIGHT NOW. AND TO HELP BETTER UNDERSTAND WHAT’S HAPPENING WITH THESE ...

states a recent study that found daily oral semaglutide (an anti-diabetic medication used for the treatment of type 2 diabetes and an anti-obesity medication used for long-term weight management ...